Paragon 28

Zimmer Biomet has completed the acquisition of Paragon 28 for an enterprise value of approximately $1.2 billion, announced in January 2025. The deal strengthens Zimmer's foot and ankle orthopaedic portfolio.

Zimmer Biomet announced a definitive agreement to acquire Paragon 28 for an upfront payment of $13.00 per share, corresponding to an equity value of approximately $1.1 billion and an enterprise value of approximately $1.2 billion.

Paragon 28 acquired the product lines of Additive Orthopaedics, including the FDA-approved 3D-printed Patient Specific Talus Spacer and a surgical planning application.